21-385 Phase I
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation
A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors
A Phase 1/2 Study of PRO1107 in Patients with Advanced Solid Tumors
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
A Phase 1/2a Study of IMM-6-415 in Participants with Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations
A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression
A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies
A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab +/-Chemotherapy as First- Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Distinguish)